IP Library Granted Patent US 10,271,540
Granted Patent B2
US 10,271,540 · App. 15/229,356 · Granted Apr 30, 2019

Medical fluid, a method of treatment and use of the fluid

Inventor: Stig Steen (Lund, SE)
Assignee: XVIVO PERFUSION AB
A01N1/0226
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,271,540
App. No.
15/229,356
Granted
Apr 30, 2019
Kind
B2
Abstract

A medical fluid for a harvested organ, tissue or part thereof, for evaluation and/or preservation. The fluid includes cocaine or a stimulating analog thereof; noradrenaline; and/or adrenaline. In addition, the fluid includes an oncotic agent, such as dextran; hormones, such as thyroxin; triiodotyronine; cortisone, insulin; and electrolytes and optionally nutrients in substantially physiological concentrations in a physiologically acceptable medium. In addition, the medical fluid further includes albumin in a concentration not exceeding 5.0%, and an oxygen carrier, such as erythrocytes. Further components may be dopamine; hydrocortisone; methylprednisolone; and a vasopressor agent, such as desmopressin. The cocaine; adrenaline; and noradrenaline are present in concentrations of each about 0.010 μM to 0.100 μM, for example in a ratio of 1:1:1.

Claims (31)

1. A method for preservation and/or evaluation of a harvested organ comprising:

circulating a medical fluid in the vascular system of the harvested organ, wherein:

the medical fluid comprises: cocaine or a cocaine analogue with stimulating effect; adrenaline; and noradrenaline; and

the harvested organ is at least partly denervated,

wherein the cocaine or the cocaine analogue is present in the medical fluid at a concentration of 0.010 μM to 0.100 μM.

2. The method according to claim 1 , wherein the medical fluid further comprises: an oncotic agent; and electrolytes in physiological concentrations in a physiologically acceptable medium.

3. The method according to claim 1 , wherein the adrenaline and the noradrenaline are present in the medical fluid at concentrations that are subphysiological.

4. The method according to claim 1 , wherein:

the adrenaline is present in the medical fluid at a concentration of 0.010 μM to 0.100 μM; and

the noradrenaline is present in the medical fluid at a concentration of 0.010 μM to 0.100 μM.

5. The method according to claim 1 , wherein the cocaine or the cocaine analogue, the adrenaline, and the noradrenaline are present in the medical fluid at concentrations that are equimolar.

6. The method according to claim 1 , wherein the harvested organ comprises a lung, lungs, or a heart.

7. The method according to claim 1 , wherein:

the medical fluid further comprises: an oncotic agent; and electrolytes in physiological concentrations in a physiologically acceptable medium; and

the adrenaline and the noradrenaline are present in the medical fluid at concentrations that are subphysiological.

8. The method according to claim 1 , wherein:

the medical fluid further comprises: an oncotic agent; and electrolytes in physiological concentrations in a physiologically acceptable medium;

the adrenaline is present in the medical fluid at a concentration of 0.010 μM to 0.100 μM; and

the noradrenaline is present in the medical fluid at a concentration of 0.010 μM to 0.100 μM.

9. The method according to claim 8 , wherein the harvested organ comprises a lung, lungs, or a heart.

10. The method according to claim 1 , wherein:

the medical fluid further comprises: an oncotic agent; and electrolytes in physiological concentrations in a physiologically acceptable medium; and

the cocaine or the cocaine analogue, the adrenaline, and the noradrenaline are present in the medical fluid at concentrations that are equimolar.

11. The method according to claim 1 , wherein the medical fluid comprises the cocaine.

12. The method according to claim 11 , wherein the medical fluid further comprises: an oncotic agent; and electrolytes in physiological concentrations in a physiologically acceptable medium.

13. The method according to claim 11 , wherein the adrenaline and the noradrenaline are present in the medical fluid at concentrations that are subphysiological.

14. The method according to claim 11 , wherein:

the adrenaline is present in the medical fluid at a concentration of 0.010 μM to 0.100 μM; and

the noradrenaline is present in the medical fluid at a concentration of 0.010 μM to 0.100 μM.

15. The method according to claim 11 , wherein the cocaine, the adrenaline, and the noradrenaline are present in the medical fluid at concentrations that are equimolar.

16. The method according to claim 11 , wherein the harvested organ comprises a lung, lungs, or a heart.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2019
From: VIVOLINE MEDICAL AB
To: XVIVO PERFUSION AB
Reel/Frame 048508/0295 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2019
From: STEEN, STIG
To: VIVOLINE MEDICAL AB
Reel/Frame 048297/0800 →
Priority Claims (1)
SE 1000518 · May 14, 2010 · national
Continuity (3)
Continuation 13697839
Provisional Application 61396709 · Jun 2, 2010
Related Publication 20160338343A1 · Nov 24, 2016